Ads
related to: schizoaffective treatment news
Search results
Results From The WOW.Com Content Network
The new schizoaffective disorder criteria continue to have questionable diagnostic validity. [5] Questionable diagnostic validity does not doubt that people with symptoms of psychosis and mood disorder need treatment—psychosis and mood disorder must be treated.
Ralmitaront (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder.
Schizoaffective disorder includes schizophrenia symptoms, such as delusions or hallucinations, and mood disorder symptoms, such as depression or mania.
Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, [4] and in the European Union in June 2007. [8] Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester .
The variation has led to the suggestion that treatment responsive and treatment resistant schizophrenia be considered as two different subtypes. [ 149 ] [ 159 ] It is further suggested that if the subtypes could be distinguished at an early stage significant implications could follow for treatment considerations, and for research. [ 154 ]
Lithium Lithium is the "classic" mood stabilizer, the first to be approved by the US FDA, and still popular in treatment. Therapeutic drug monitoring is required to ensure lithium levels remain in the therapeutic range: 0.6 to 0.8 or 0.8–1.2 mEq/L (or millimolar).
Ads
related to: schizoaffective treatment news